Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.457
-0.022 (-4.64%)
At close: Dec 5, 2025, 4:00 PM EST
0.457
+0.001 (0.15%)
After-hours: Dec 5, 2025, 7:59 PM EST
Incannex Healthcare Revenue
Incannex Healthcare had revenue of $12.00K in the twelve months ending September 30, 2025, down -86.05% year-over-year. In the fiscal year ending June 30, 2025, Incannex Healthcare had annual revenue of $86.00K with 616.67% growth.
Revenue (ttm)
$12.00K
Revenue Growth
-86.05%
P/S Ratio
13,173.88
Revenue / Employee
$1,000
Employees
12
Market Cap
158.09M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IXHL News
- 2 days ago - Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) - GlobeNewsWire
- 15 days ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026 - Newsfile Corp
- 5 weeks ago - Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus - GlobeNewsWire
- 6 weeks ago - Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder - GlobeNewsWire
- 3 months ago - Incannex Healthcare Authorizes $20 Million Share Repurchase Program - GlobeNewsWire
- 3 months ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update - Newsfile Corp
- 4 months ago - Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea - GlobeNewsWire